本文選題：普羅布考 + 血管功能��； 參考：《中南大學(xué)》2014年博士論文

【摘要】：第一部分Probucol通過促進eNOS活化保護H202誘導(dǎo)的內(nèi)皮依賴性血管舒張功能的降低 背景 普羅布考(Probucol, PB,又名丙丁酚)是一種人工合成的抗氧化劑。它作為一種雙酚類化合物,具有降低膽固醇、抗氧化、抗炎及抗動脈粥樣硬化等多重作用,最初是作為降脂藥物應(yīng)用于臨床。臨床試驗、動物及體外實驗發(fā)現(xiàn)probucol對某些病理改變下血管收縮舒張功能有直接作用,并證實其對血管功能的作用獨立于其降脂效果。氧化應(yīng)激是高血壓、動脈粥樣硬化等心血管疾病的發(fā)病機制,氧化應(yīng)激通過作用于血管細胞,從而影響血管的收縮和舒張活性。而probucol的抗氧化性不僅表現(xiàn)在抑制脂質(zhì)(如低密度脂蛋白LDL)的氧化,也可以清除血液和組織中自由基,這提示probucol的抗氧化作用是否是其影響氧化應(yīng)激下血管功能改變的機制,以及是否對于心血管疾病的血管舒縮功能有保護作用。 血管內(nèi)皮是維持血管穩(wěn)態(tài)的主要調(diào)節(jié)者。已知內(nèi)皮細胞是血管收縮和舒張活性的重要組成部分,而內(nèi)皮功能障礙可以導(dǎo)致血管收縮及舒張功能平衡紊亂,血壓調(diào)節(jié)異常；此外內(nèi)皮細胞受損還可以導(dǎo)致血液細胞黏附增加,炎癥細胞浸潤血管以及促-抗凝血平衡失調(diào)等。臨床試驗證實內(nèi)皮細胞功能障礙是心血管事件的危險因素之一。而氧化應(yīng)激對血管性疾病的發(fā)生發(fā)展有促進作用,活性氧族(reactive oxygen species, ROS)首先破壞內(nèi)皮細胞功能,影響內(nèi)皮的調(diào)壓、抗凝及內(nèi)分泌合成功能,這可能是動脈粥樣硬化、高血壓、糖尿病等血管病變的原因之一。 目的 Probucol多效性作用機制尚不明確,而且probucol對血管舒縮功能的作用仍有爭議。本實驗為了探討probucol對血管收縮及舒張功能的作用；并根據(jù)probucol的抗氧化特性進一步探討,在H2O2誘導(dǎo)氧化損傷基礎(chǔ)下probucol對血管舒張功能的影響及作用機制。 方法 使用大鼠離體胸主動脈血管環(huán)構(gòu)建H2O2損傷內(nèi)皮依賴性血管舒張功能的模型。(1)使用myograph技術(shù)研究離體血管環(huán)的收縮及舒張功能,使用高鉀(KCl)、去氧腎上腺素(PE)分別誘導(dǎo)血管收縮反應(yīng),乙酰膽堿(ACh)、硝普鈉(SNP)誘導(dǎo)血管舒張反應(yīng)(內(nèi)皮依賴性和非內(nèi)皮依賴性)。觀察血管在H2O2的持續(xù)作用下,血管基礎(chǔ)功能的變化情況。(2)在H2O2作用的基礎(chǔ)上,myograph檢測PB干預(yù)處理對血管功能的影響,并且使用western blot技術(shù)檢測干預(yù)后血管環(huán)內(nèi)皮特異性一氧化氮合酶(eNOS)蛋白的表達情況,探討PB對血管環(huán)舒張功能的作用是否是通過影響內(nèi)皮細胞eNOS的產(chǎn)生來實現(xiàn)的。(3)使用血管環(huán)組織培養(yǎng)技術(shù)進一步探討PB對不良應(yīng)激下內(nèi)皮依賴性舒張功能的作用,myograph檢測培養(yǎng)后血管環(huán)活性的改變。 建立apoE-/-動脈粥樣硬化小鼠模型,在體實驗研究在動脈粥樣硬化疾病血管損傷基礎(chǔ)上PB對血管舒張功能的影響,及其對血脂代謝的作用與血管功能改變的相關(guān)性 培養(yǎng)原代人臍靜脈內(nèi)皮細胞(HUVECs),同樣在體外實驗中建立H202損傷血管內(nèi)皮功能的模型,主要進行以下實驗：(1) HUVECs的培養(yǎng)及鑒定；(2)實時熒光定量RT-qPCR及western blot檢測PB對內(nèi)皮細胞eNOS mRNA、蛋白表達水平的影響,對eNOS活化程度的影響；(2)在H2O2損傷情況下,PB對內(nèi)皮細胞eNOS表達水平的作用,探討PB是否通過影響eNOS表達來保護內(nèi)皮細胞功能；(3)免疫熒光顯微鏡觀察以及熒光定量檢測HUVEC在H2O2誘導(dǎo)氧化損傷時NO的生成,以及PB對NO產(chǎn)生的作用,探討PB是否能激活eNOS-NO生成途徑達到保護內(nèi)皮介導(dǎo)舒張功能的作用。 結(jié)果 1.H2O2在一定濃度及作用時間下可以誘導(dǎo)氧化損傷,選擇性抑制大鼠離體胸主動脈血管環(huán)ACh誘導(dǎo)的內(nèi)皮依賴性舒張功能,對血管收縮功能無明顯作用。高濃度或長時間H2O2作用可以造成不可逆的血管收縮及舒張功能的喪失。 2.在H2O2誘導(dǎo)的氧化應(yīng)激下,PB (5-20μM)保護大鼠及小鼠離體胸主動脈血管環(huán)ACh誘導(dǎo)的內(nèi)皮依賴性血管舒張功能。 3.PB通過抑制H2O2誘導(dǎo)的離體血管環(huán)eNOS活性下降,保護內(nèi)皮細胞功能,但對收縮功能無顯著作用。 4.在組織培養(yǎng)過程中,PB對大鼠胸主動脈血管環(huán)的內(nèi)皮依賴性舒張功能也有保護作用。 5.在apoE-/-動脈粥樣硬化小鼠模型中,PB可以保護小鼠主動脈內(nèi)皮依賴性舒張功能,且該作用與其降脂效果無關(guān)。 6.PB可以提高人臍靜脈內(nèi)皮細胞中p-eNOS/eNOS比值,促進eNOS的磷酸化程度(Ser-1177),激活eNOS氧化活性；H2O2抑制eNOS總蛋白表達水平,PB保護H2O2誘導(dǎo)氧化損傷情況下eNOS的磷酸化水平。 7.PB促進人臍靜脈內(nèi)皮細胞中eNOS活化的產(chǎn)物NO的產(chǎn)生。 結(jié)論 PB對于H2O2誘導(dǎo)的內(nèi)皮依賴性舒張功能障礙有保護作用,其機制可能是PB通過促進eNOS磷酸化,激活eNOS氧化酶活性,從而促進NO的生成有關(guān)。 第二部分普羅布考對平滑肌細胞表型的作用及其與平滑肌細胞增殖遷移的關(guān)系 背景 血管平滑肌細胞VSMCs作為血管壁的重要構(gòu)成部分,其功能的異常與心血管疾病有密切關(guān)系。VSMCs增殖及合成作用參與動脈粥樣硬化斑塊的形成,平滑肌細胞源性泡沫細胞是斑塊的細胞成分之一。傳統(tǒng)觀點認為平滑肌細胞具有收縮型及合成型兩種表型,而病理改變與合成/增殖型有關(guān)。而新觀點認為病變血管周圍或血液來源的干細胞才是斑塊形成的主要細胞來源,它們擁有部分SMC表型標記,但不同于普通平滑肌細胞的功能,擁有更多干細胞的特性,因此提出這種多能干細胞性的平滑肌細胞是SMC參與血管病理改變的基礎(chǔ)。因此SMC干細胞活性增加與血管病灶處SMC增殖或合成作用有關(guān),主要以高分化平滑肌細胞收縮蛋白的降低(包括α-actin、SM22、calponin及SM-MHC (SM1、SM2))以及干細胞標志升高。 動物實驗發(fā)現(xiàn)probucol可以抑制家兔主動脈球囊擴張損傷后血管再狹窄,抑制平滑肌細胞增殖和遷移,抑制內(nèi)膜增厚、管腔變窄,并且改善血管重構(gòu)。因此我們從SMC對血管疾病的作用機理和表型變化出發(fā),探討PB的對心血管疾病的保護作用是否與SMC表型有關(guān),及其對SMC增殖遷移的作用。 目的 探索probucol對平滑肌細胞增殖及遷移的作用以及該作用是否與平滑肌細胞的表型變化有關(guān)。 方法 (1)使用組織塊貼壁法提取并培養(yǎng)原代大鼠的血管平滑肌細胞,使用免疫熒光染色鑒定原代VSMCs。觀察原代細胞提取和培養(yǎng)過程中細胞形態(tài)及增殖分化過程,使用PB干預(yù)血管組織塊以觀察細胞從組織塊原位的遷出情況；并且在細胞接種過程中直接計數(shù)PB對細胞增殖數(shù)目的影響。 (2)使用Transwell細胞遷移實驗檢測PB及oxLDL對VSMCs的遷移影響 (3)采用RT-qPCR技術(shù)、western-blot技術(shù)研究VSMCs中表型相關(guān)蛋白α-actin、干細胞標志Sox-10的表達變化,以及平滑肌細胞轉(zhuǎn)錄激活因子myocardin的表達改變情況。 結(jié)果(1) α-actin+SM22+Sox-10-是高分化VSMCs的表型特征； (2)PB單獨作用抑制VSMCs干細胞標志Sox-10的表達,也抑制myocardin、SM22表達,但不影響收縮蛋白α-actin的表達。H202誘導(dǎo)氧化應(yīng)激促進Sox-10表達并下調(diào)myocardin表達,而PB可以部分逆轉(zhuǎn)該變化,即H2O2作用基礎(chǔ)上PB抑制Sox-10,促進myocardin表達。 (3)PB抑制VSMCs從組織內(nèi)遷移以及在體外培養(yǎng)過程中的遷移及增殖速率； 結(jié)論 在體外研究中發(fā)現(xiàn)PB可以抑制大鼠VSMCs的遷移及增殖,其機制可能與PB抑制平滑肌干細胞的分化及運動能力有關(guān)。
[Abstract]:The first part of Probucol protects H202 induced endothelium-dependent vasodilation by promoting eNOS activation.
background
Probucol (PB, also known proproopol) is a synthetic antioxidant. It is a kind of bisphenol compound, which has multiple effects on lowering cholesterol, antioxidation, anti-inflammatory and anti atherosclerosis. It was first used as a lipid lowering drug in clinical practice. In clinical trials, animal and in vitro experiments found probucol to some pathology. The function of vasoconstriction and vasodilatation has a direct effect, and it is confirmed that its effect on vascular function is independent of its lipid lowering effect. Oxidative stress is the pathogenesis of cardiovascular diseases such as hypertension and atherosclerosis. Oxidative stress acts on vascular cells and thus affects vasoconstrictor and diastolic activity of blood vessels. The antioxidant activity of probucol is not Only the inhibition of lipid (such as low density lipoprotein LDL) oxidation can also remove free radicals in the blood and tissue, which suggests that the antioxidant effect of probucol is the mechanism that affects the changes in vascular function under oxidative stress, and whether it has protective effects on vascular systolic function in cardiovascular disease.
Vascular endothelium is the main regulator for the maintenance of vascular homeostasis. Known endothelial cells are an important component of vasoconstriction and diastolic activity. Endothelial dysfunction can lead to a balance disorder of vasoconstriction and diastolic function, abnormal blood pressure regulation, and endothelial cell damage can also lead to increased blood cell adhesion and inflammatory cell infiltration. Blood vessels and anticoagulant balance disorders. Clinical trials have confirmed that endothelial dysfunction is one of the risk factors for cardiovascular events. Oxidative stress can promote the development of vascular diseases. Reactive oxygen species (ROS) first destroys endothelial cell function, affects endothelial pressure, anticoagulant and internal components. Secretory function, which may be one of the causes of atherosclerosis, hypertension, diabetes and other vascular diseases.
objective
The mechanism of Probucol's pleiotropic action is still unclear, and the effect of probucol on vasomotor function is still controversial. This experiment is to explore the effect of probucol on vasoconstriction and diastolic function, and further explore the effect of probucol on vasodilatation based on H2O2 induced oxidative damage and the effect of probucol on vasodilatation. Use the mechanism.
Method
A model of endothelium-dependent vasodilatation of H2O2 injury was constructed using the isolated thoracic aorta ring of rats. (1) the systolic and diastolic function of the isolated vascular rings was studied by myograph technique. The vasoconstrictor response was induced by high potassium (KCl), deoxyadrenaline (PE), acetylcholine (ACh), and sodium nitroprusside (SNP) induced vasodilatation. Skin dependence and non endothelium-dependent). Observe the changes of vascular basic function under the continuous action of H2O2. (2) on the basis of H2O2 action, myograph detected the effect of PB intervention on vascular function, and the expression of endothelial specific nitric oxide synthase (eNOS) protein expression after intervention using Western blot technique. To investigate whether the effect of PB on vascular ring diastolic function is achieved by affecting the production of eNOS in endothelial cells. (3) the effect of PB on endothelium dependent vasodilatation under adverse stress, and the changes of vascular ring activity after myograph were detected by vascular ring tissue culture.
The effect of PB on vasodilatation on the basis of vascular injury of atherosclerotic disease, and the correlation between the role of blood lipid metabolism and vascular function change in the experimental study of atherosclerotic apoE-/- mice model was established in vivo.
The primary human umbilical vein endothelial cells (HUVECs) were cultured and the models of vascular endothelial function damaged by H202 were also established in vitro. The following experiments were carried out: (1) the culture and identification of HUVECs; (2) the effect of real-time fluorescence quantitative RT-qPCR and Western blot on the level of eNOS mRNA and protein expression of endothelial cells, and the activation degree of eNOS. (2) (2) the effect of PB on the expression level of eNOS in endothelial cells and whether PB protects endothelial cell function by affecting the expression of eNOS; (3) immunofluorescence microscope observation and fluorescence quantitative detection of NO production in H2O2 induced oxidative damage, and the effect of PB on NO, and to explore whether PB can activate eNOS -NO production pathway can protect endothelial mediated diastolic function.
Result
1.H2O2 can induce oxidative damage in a certain concentration and time of action and selectively inhibit endothelium dependent vasodilatation induced by ACh in the isolated thoracic aorta ring of the rat, which has no obvious effect on the vasoconstrictor function. High concentration or long time H2O2 can cause irreversible loss of vasoconstriction and diastolic function.
2. under the oxidative stress induced by H2O2, PB (5-20 M) protects ACh induced endothelium-dependent vasodilation function in isolated rat thoracic aorta rings.
3.PB inhibited endothelial function induced by H2O2 induced decrease of eNOS activity in isolated vascular rings, but had no significant effect on contractile function.
4. in tissue culture, PB also has protective effects on endothelium-dependent vasodilation of thoracic aorta rings in rats.
5. in the apoE-/- atherosclerosis mouse model, PB can protect the endothelium-dependent vasodilatation function of mice, and this effect has nothing to do with the lipid-lowering effect.
6.PB can increase the p-eNOS/eNOS ratio in human umbilical vein endothelial cells, promote the phosphorylation of eNOS (Ser-1177), activate eNOS oxidation activity, H2O2 to inhibit the expression level of eNOS total protein, PB protects the phosphorylation level of eNOS under the condition of H2O2 induced oxidative damage.
7.PB promotes the production of NO activated by eNOS in human umbilical vein endothelial cells.
conclusion
PB has a protective effect on H2O2 induced endothelium-dependent diastolic dysfunction. The mechanism may be that PB promotes the production of NO by promoting the phosphorylation of eNOS, activating the activity of eNOS oxidase, and thus promoting the formation of NO.
The second part of probucol on the phenotype of smooth muscle cells and its relationship with smooth muscle cell proliferation and migration
background
Vascular smooth muscle cell VSMCs is an important component of vascular wall. The abnormal function of vascular smooth muscle cells is closely related to cardiovascular disease..VSMCs proliferation and synthesis are involved in the formation of atherosclerotic plaques. Smooth muscle cell derived foam cells are one of the cellular components of plaque. Two phenotypes are formed, and pathological changes are associated with synthesis / proliferation. The new view is that the stem cells around the vessel or blood source are the main source of the plaque formation. They have some SMC phenotypic markers, but they are different from the function of ordinary smooth muscle cells and have more characteristics of stem cells. Therefore, this multipotent stem is proposed. Cellular smooth muscle cells are the basis of SMC's involvement in vascular pathological changes. Therefore, the increase of SMC stem cell activity is related to the proliferation or synthesis of SMC in vascular lesions, mainly with the decrease of contractile proteins of highly differentiated smooth muscle cells (including alpha -actin, SM22, calponin and SM-MHC (SM1, SM2)) and the rise of stem cell markers.
Animal experiments have found that probucol can inhibit vascular restenosis after balloon dilatation of rabbit aorta, inhibit the proliferation and migration of smooth muscle cells, inhibit intima thickening, narrowing of the lumen, and improve vascular remodeling. Therefore, we discuss the protective effect of PB on cardiovascular disease from the mechanism and phenotypic changes of SMC to vascular disease. Whether it is related to SMC phenotype and its effect on SMC proliferation and migration.
objective
To explore the effect of probucol on the proliferation and migration of smooth muscle cells and whether it is related to the phenotypic changes of smooth muscle cells.
Method
(1) the vascular smooth muscle cells of the primary rat were extracted and cultured with tissue block wall method, and the primary VSMCs. was detected by immunofluorescence staining to observe the cell morphology and proliferation and differentiation process during the extraction and culture of the primary cells. PB was used to intervene the vascular tissue in order to observe the migration of the cells from the group in situ; and the cells were inoculated in the cells. The effect of direct counting of PB on cell proliferation was studied.
(2) using Transwell cell migration assay to detect the effects of PB and oxLDL on VSMCs migration.
(3) RT-qPCR technology and Western-blot technique were used to study the phenotypic related protein alpha -actin in VSMCs, the expression of Sox-10 in stem cells, and the change of the expression of the transcriptional activator of smooth muscle cells (myocardin).
Results (1) alpha -actin+SM22+Sox-10- is a phenotypic characteristic of highly differentiated VSMCs.
(2) PB alone inhibits the expression of VSMCs stem cell marker Sox-10 and inhibits myocardin, SM22 expression, but does not affect the expression of Sox-10 induced by the expression of contractile protein alpha -actin to induce oxidative stress to promote Sox-10 expression and down regulation of myocardin expression, while PB can partly reverse the change.
(3) PB inhibited the migration of VSMCs from tissues and the migration and proliferation rate in vitro.
conclusion
In vitro studies showed that PB could inhibit the migration and proliferation of VSMCs in rats. The mechanism may be related to the inhibition of PB on the differentiation and motor ability of smooth muscle stem cells.

【學(xué)位授予單位】：中南大學(xué)
【學(xué)位級別】：博士
【學(xué)位授予年份】：2014
【分類號】：R96

【相似文獻】

相關(guān)期刊論文 前10條

1 朱冰坡;范利;;抗氧化制劑普羅布考的臨床研究現(xiàn)狀[J];解放軍保健醫(yī)學(xué)雜志;2005年04期

2 劉朋;;普羅布考抗動脈粥樣硬化作用機制及研究進展[J];天津藥學(xué);2009年03期

3 李婷婷;郭媛;;普羅布考抗動脈粥樣硬化作用機制及研究進展[J];醫(yī)學(xué)綜述;2009年09期

4 張寶紅;劉改云;王光耀;;普羅布考對頸動脈粥樣硬化斑塊作用的臨床研究[J];包頭醫(yī)學(xué)院學(xué)報;2009年05期

5 姜磊;王珍霞;;普羅布考在老年不穩(wěn)定型心絞痛患者治療中的作用[J];吉林醫(yī)學(xué);2010年28期

6 陳忠平;張入銘;蔣蘇平;劉江華;;普羅布考治療非增殖型糖尿病視網(wǎng)膜病變臨床觀察[J];中國動脈硬化雜志;2010年07期

7 蔣美媛;;普羅布考防治動脈粥樣硬化性疾病的臨床研究[J];內(nèi)科;2012年03期

8 溫建華,王文信,方樹青,陸輝明,黃飛龍,盧國華;降血脂藥——普羅布考[J];中國新藥雜志;1998年01期

9 陳志,田瑋;普羅布考治療冠心病88例臨床療效觀察[J];實用心腦肺血管病雜志;2004年01期

10 尹瑞興,卡扎里,劉唐威,陶新智,朱立光,梁文武;普羅布考對缺血再灌注心肌細胞凋亡的作用(英文)[J];中國臨床康復(fù);2004年24期

相關(guān)會議論文 前10條

1 趙凱;李永健;;普羅布考對老年不穩(wěn)定型心絞痛患者對比劑腎損害的預(yù)防作用[A];中華醫(yī)學(xué)會第十五次全國心血管病學(xué)大會論文匯編[C];2013年

2 梅斌;章軍建;劉煜敏;;兔頸動脈血管成形術(shù)后普羅布考對血管內(nèi)膜生長因子的影響[A];第十一屆全國神經(jīng)病學(xué)學(xué)術(shù)會議論文匯編[C];2008年

3 江俊麟;張曉紅;鄧漢武;李元建;;普羅布考保護內(nèi)皮細胞損傷與降低內(nèi)源性一氧化氮合酶抑制物的關(guān)系[A];湖南省生理科學(xué)學(xué)會2004年度學(xué)術(shù)年會論文摘要匯編[C];2004年

4 檀國軍;任國勇;;普羅布考對實驗性自身免疫性腦脊髓炎大鼠血腦屏障的干預(yù)作用及可能機制[A];山東省2013年神經(jīng)內(nèi)科學(xué)學(xué)術(shù)會議暨中國神經(jīng)免疫大會2013論文匯編[C];2013年

5 卜海富;劉德寶;桂斌捷;;聯(lián)合應(yīng)用普羅布考、阿司匹林預(yù)防兔激素性股骨頭缺血性壞死的實驗研究[A];第二屆華東地區(qū)骨科學(xué)術(shù)大會暨山東省第九次骨科學(xué)術(shù)會議論文匯編[C];2007年

6 劉玲;鐘玲;廖曉輝;陳建偉;張玲;;普羅布考改善同型半胱氨酸導(dǎo)致的人血管內(nèi)皮細胞增殖抑制作用[A];西南地區(qū)第12屆腎臟病學(xué)術(shù)會議暨貴州省醫(yī)學(xué)會腎臟病學(xué)分會2012年學(xué)術(shù)會議論文集[C];2012年

7 蔣曉真;趙曉暉;陳蕊華;顧哲;顧佩莉;周斌;朱震宏;徐凌燕;鄒宇峰;;普羅布考對2型糖尿病輕度認知功能障礙患者的干預(yù)治療[A];中華醫(yī)學(xué)會第十二次全國內(nèi)分泌學(xué)學(xué)術(shù)會議論文匯編[C];2013年

8 金雪婷;孫愛軍;王克強;鄒云增;葛均波;;普羅布考抑制氧化低密度脂蛋白誘導(dǎo)的人樹突狀細胞免疫功能成熟及作用機制研究[A];第十三次全國心血管病學(xué)術(shù)會議論文集[C];2011年

9 王成鳳;劉群;;阿司匹林聯(lián)合普羅布考治療短暫性腦缺血發(fā)作的臨床觀察[A];第十一屆全國神經(jīng)病學(xué)學(xué)術(shù)會議論文匯編[C];2008年

10 歐柏青;姜德謙;張社兵;張小煉;劉虹;田軼倫;;普羅布考抑制氧化低密度脂蛋白誘導(dǎo)人臍靜脈內(nèi)皮細胞Fractalkine的表達[A];中華醫(yī)學(xué)會心血管病學(xué)分會第十次全國心血管病學(xué)術(shù)會議匯編[C];2008年

相關(guān)重要報紙文章 前1條

1 記者 李天舒;老藥新用保護腎功能[N];健康報;2009年

相關(guān)博士學(xué)位論文 前8條

1 倪占玲;普羅布考促進小鼠巨噬細胞膽固醇逆轉(zhuǎn)運的體內(nèi)外實驗研究[D];中南大學(xué);2007年

2 吳蓉;降脂藥普羅布考改善大鼠非酒精性脂肪性肝炎的機制研究[D];重慶醫(yī)科大學(xué);2012年

3 洪紹彩;普羅布考降高密度脂蛋白膽固醇及抗動脈粥樣硬化機制的實驗研究[D];中南大學(xué);2006年

4 金雪婷;普羅布考通過樹突狀細胞抗動脈粥樣硬化的機制的研究[D];復(fù)旦大學(xué);2012年

5 富華穎;普羅布考對糖尿病兔心房重構(gòu)及心房顫動發(fā)生的影響[D];天津醫(yī)科大學(xué);2012年

6 歐柏青;趨化因子Fractalkine及其受體在動脈粥樣硬化發(fā)病中的作用及氟伐他汀/普羅布考的干預(yù)研究[D];中南大學(xué);2008年

7 焦占全;糖尿病大鼠造影劑急性腎損害機制及普羅布考保護作用的實驗研究[D];天津醫(yī)科大學(xué);2012年

8 楊寧;普羅布考、厄貝沙坦對胰島素PI3K/Akt信號轉(zhuǎn)導(dǎo)通路及高血壓相關(guān)因素影響的實驗研究[D];天津醫(yī)科大學(xué);2009年

相關(guān)碩士學(xué)位論文 前10條

1 徐曉娜;普羅布考對兔動脈粥樣硬化模型中斑塊穩(wěn)定性及熱休克蛋白60表達的影響[D];天津醫(yī)科大學(xué);2008年

2 邵利娟;普羅布考對氧化誘導(dǎo)的血管平滑肌細胞增殖和凋亡的研究[D];山東大學(xué);2009年

3 宋征宇;普羅布考在大鼠腦組織中的抗氧化作用研究[D];天津醫(yī)科大學(xué);2011年

4 鐘建開;普羅布考在動脈粥樣硬化模型中改善高密度脂蛋白功能的研究[D];南方醫(yī)科大學(xué);2011年

5 張建寧;普羅布考通過誘導(dǎo)血紅素加氧酶1發(fā)揮抗動脈粥樣硬化作用[D];山東大學(xué);2012年

6 鄭宗菊;普羅布考抗動脈粥樣硬化療效觀察[D];重慶醫(yī)科大學(xué);2013年

7 朱冰坡;普羅布考對老年下肢動脈硬化癥患者血管內(nèi)皮功能以及抗氧化—抗炎癥作用的初步研究[D];中國人民解放軍軍醫(yī)進修學(xué)院;2005年

8 任國勇;普羅布考對實驗性自身免疫性腦脊髓炎大鼠血腦屏障的干預(yù)作用及可能機制[D];河北醫(yī)科大學(xué);2013年

9 BINAY KUMAR ADHIKARI;比較阿托伐他汀與聯(lián)合應(yīng)用普羅布考對冠狀動脈粥樣硬化患者血漿LDL-C達標水平的影響[D];吉林大學(xué);2014年

10 王成鳳;阿司匹林聯(lián)合普羅布考治療短暫性腦缺血發(fā)作的臨床觀察[D];吉林大學(xué);2008年

，

本文編號：1851326